Abbott to acquire Exact Sciences for $21 billion
Abbott is eyeing to become a global powerhouse in early cancer detection and precision oncology
Abbott is eyeing to become a global powerhouse in early cancer detection and precision oncology
New PARTNER trial sub-study data show that post-operative ctDNA detection using tumour-informed MRD assays can accurately predict distant recurrence risk in triple-negative breast cancer patients
Subscribe To Our Newsletter & Stay Updated